Elon knows the truth, which is why they want him silenced

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.

Watch this new documentary and you’ll discover what Elon knows,

William P. Burke net worth and biography

William Burke Biography and Net Worth

CFO of Haemonetics

William P. Burke serves as Chief Financial Officer, Executive Vice President of the Company. From July 2014 to July 2016, Mr. Burke served as Chief Integration Officer and Vice President, Integration for Medtronic plc, a global healthcare products company and was a member of its Executive Committee. In that role, Mr. Burke was responsible for ensuring the successful integration of Medtronic with Covidien plc, a global healthcare company, following its acquisition by Medtronic. Prior to joining Medtronic, Mr. Burke spent more than 20 years in finance and business development leadership roles at Covidien, including Chief Financial Officer for Covidien Europe based in Zurich, Vice President of Corporate Strategy and Portfolio Management and Vice President of Financial Planning and Analysis. Previously, Mr. Burke also held key positions within Tyco Healthcare, including the Financial Controller of Valleylab, Managing Director of the Covidien Group in Switzerland and International Controller. He began his career as an auditor with KPMG. Mr. Burke received a Bachelor of Science degree in Business Administration from Bryant College.

How do I contact William P. Burke?: The corporate mailing address for Mr. Burke and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on William P. Burke's contact information.
Has William P. Burke been buying or selling shares of Haemonetics?: William P. Burke has not been actively trading shares of Haemonetics over the course of the past ninety days. Learn More on William P. Burke's trading history.
Who are Haemonetics' active insiders?: Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.
Are insiders buying or selling shares of Haemonetics?: During the last twelve months, insiders at the medical instruments supplier sold shares 9 times. They sold a total of 33,828 shares worth more than $3,031,094.99. The most recent insider tranaction occured on July, 26th when insider Stewart W Strong sold 4,312 shares worth more than $393,038.80. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.
Information on this page was last updated on 7/26/2024.

William P. Burke Insider Trading History at Haemonetics

William P. Burke Buying and Selling Activity at Haemonetics

Haemonetics Company Overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $89.22

$88.64

$91.43

50 Day Range

MA: $77.55

$71.15

$93.38

2 Week Range

Now: $89.22

$70.25

$97.97

Volume

564,400 shs

Average Volume

555,780 shs

Market Capitalization

$4.48 billion

P/E Ratio

37.02

Dividend Yield

N/A

Beta

0.32